The pursuit of TIGIT as a therapeutic target has led to the development of monoclonal antibodies that bind to the TIGIT receptor on T cells and NK cells, showing promising results in reducing tumor growth and enhancing survival in various cancer models, including myeloma, and providing protection against tumor metastasis and recurrence [33]. Here, TIGIT is linked to plasma cell myeloma.